title: Sneaky side effects and ineffectiveness of an immunotherapy with ipilimumab in a case of metastatic melanoma.
abstract: Ipilimumab is an anti-CTLA-4 antibody that is approved for the treatment of metastatic malignant melanoma. Side-effects are mostly immune-mediated and in many cases the lack of specific symptoms leads to delayed diagnosis and treatment of adverse events. We present the case of a female patient who experienced an uncommon combination of adverse reactions while undergoing therapy with ipilimumab and where the absence of specificity of the symptoms led to late diagnosis and treatment of side effects. Autoimmune disease was neither associated with tumor response nor with prolonged survival.
authors: Department of Dermatology, Saarland University Medical School , Homburg/Saar, Germany.
authors: Nathalie
authors: N
authors: Krecké
authors: Department for Diagnostic and Interventional Neuroradiology, Saarland University Medical School , Homburg/Saar, Germany.
authors: Anna
authors: A
authors: Zimmer
authors: Department of Internal Medicine II, Saarland University Medical School , Homburg/Saar, Germany.
authors: Bettina
authors: B
authors: Friesenhahn-Ochs
authors: Department of Dermatology, Saarland University Medical School , Homburg/Saar, Germany.
authors: Cornelia S L
authors: CS
authors: Müller
authors: Department of Dermatology, Saarland University Medical School , Homburg/Saar, Germany.
authors: Thomas
authors: T
authors: Vogt
authors: Department of Dermatology, Saarland University Medical School , Homburg/Saar, Germany.
authors: Claudia
authors: C
authors: Pföhler
keywords: autoimmunity; immunology; ipilimumab; melanoma; orbital myositis; side effects; vitiligo